Society
Moderna and Merck's mRNA Cancer Vaccine Reduces Melanoma Recurrence Risk
Final-stage trial results show Moderna and Merck's personalized mRNA vaccine Intismeran reduces the risk of melanoma recurrence and metastasis, marking a first for mRNA cancer vaccines in large-scale trials. Moderna's stock surged 160% on the news, and the companies are in talks with regulators. Experts suggest the results could herald a new era in solid tumor treatment.